This study aims to evaluate the effectiveness and safety of a new medication called Eloralintide, also known as LY3841136. The research focuses on individuals living with Obesity, which is a condition involving excessive body fat, or being Overweight, which means having a body weight that is higher than what is considered healthy for a given height. The participants included in this study may or may not also have Type 2 Diabetes, a chronic condition that affects how the body processes blood sugar. Some individuals in the study are already using a weekly Incretin, which is a type of medication that helps regulate blood sugar and digestion.

During the study, participants will receive either Eloralintide or a placebo through subcutaneous use, which means the medication is injected into the fatty tissue just under the skin. The medication is provided in a pre-filled syringe for once-weekly administration. This is a randomized and double-blind study, meaning that neither the participants nor the researchers know beforehand which treatment is being administered. This method is used to ensure the results are as objective as possible.